Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Mol Cancer Res. 2013 Oct 3;11(12):1585–1596. doi: 10.1158/1541-7786.MCR-13-0358

Table 1.

Pathway level impact analysis using genes differentially expressed in resistant/bevacizumab tumors compared to parental/bevacizumab tumors.

S.No. Pathway Name Genes
Upregulated		 Impact
Factor		 P-value
1 Phosphatidylinositol signaling system PLCg2, ARHGEF16 25.009 3.58E-10
2 Pathways in cancer FGF2, FGFR3, PLCG2, FZD4, IGFBP6, IRS1, GRB10, CCNB2, CCND3, CDC42EP4, TP63, CAPN1 8.601 1.77E-4
3 Cytokine-cytokine receptor interaction CXCR7, CX3CL1, CCL5, IL20RB 5.551 2.5E-2
4 Cell cycle CCNB2, CCND3, CDC42EP4 5.163 3.53E-2
5 Apoptosis IRF1, TNFSF10, PARP9, CRABP2, CASP1 4.866 4.52E-2